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ABSTRACT: Specialized proresolving mediators (SPMs) biosynthesized from docosahexaenoic acids (DHAs) in-
cluding resolvins (Rvs), protectins, and maresins are potent endogenous autacoids that actively resolve in-
flammation, protect organs, and stimulate tissue regeneration. Our hypothesis was that failure of resolution
programs may lead to unremitting inflammation in obesity, contributing to the development of metabolic comor-
bidities in this condition. Obese individuals with persistent low-grade systemic inflammation showed reduced
leukocyte production of the DHA-derived monohydroxy fatty acid 17– hydroxy-DHA (HDHA) and unbalanced
formation of SPMs (in particular D-series Rvs) accompanied by enhanced production of proinflammatory lipid
mediators such as leukotriene B4.Mechanistic studies attributed this impairment to reduced 15-lipoxygenase (LOX)
activity rather thanalteredDHAcellularuptake.Moreover, leukocytes fromobese individualsexhibiteddecreased5-
LOX levels and reduced 5-LOXSer271phosphorylation anddistinct intracellular 5-LOX redistribution.However, 15-
LOX appears to be the most critical factor for the deficient production of SPMs by obese leukocytes because the
formation of D-series Rvs was completely rescued by incubation with the intermediate precursor 17-HDHA. These
data provide proof of concept that administration of intermediate precursors of SPM biosynthesis (e.g., 17-HDHA)
could be more efficient in overriding impaired formation of these proresolving lipid mediators in conditions char-
acterizedbydysfunctional LOXactivity, such as obesity.—López-Vicario,C., Titos, E.,Walker,M.E.,Alcaraz-Quiles,
J., Casulleras,M.,Durán-Güell,M., Flores-Costa,R., Pérez-Romero,N., Forné,M.,Dalli, J., Clària, J. Leukocytes from
obese individuals exhibit an impaired SPM signature. FASEB J. 33, 000–000 (2019). www.fasebj.org
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A persistent subclinical state of low-grade inflammation
largelydictates theprogressionofmetabolic complications
in obese individuals such as insulin resistance, athero-
sclerosis, type 2 diabetes, and nonalcoholic fatty liver
disease (NAFLD) (1, 2). This state of low-grade in-
flammation associated with obesity involves many com-
ponents of the classic inflammatory response topathogens
and includes systemic increases in circulating in-
flammatory cytokines and acute phase proteins (e.g.,
C-reactive protein), decreases in insulin-sensitizing and
anti-inflammatory factors such as adiponectin, and re-
cruitment and subsequent activation of leukocytes into
inflamed tissues (3, 4). The nature of obesity-induced in-
flammation, which is known as meta-inflammation, is
unique compared with other inflammatory conditions
because it is characterized by tonic low-grade activation of
the immune system in the absence of active infection and
in response to recurrent episodes of overnutrition (5).
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Moreover, unremitting inflammation in obese individuals
could also be the consequence of an intrinsic inability to
resolve the chronic state of low-grade inflammation (5).
Current evidence indicates that inflammation does not
switchoff inapassivemannerbut rather involvesaprogram
of unique endogenous mechanisms and mediators that or-
chestrate active resolution in a timely and effective manner
(6, 7). Among these, lipid mediators such as lipoxins (LXs),
resolvins (Rvs), protectins, and maresins (MaRs), collec-
tively knownas specializedproresolvingmediators (SPMs),
have attracted themost attention (6, 7). SPMsnot only act as
“braking signals” of the persistent vicious cycle leading to
unremitting inflammation but also mainly as promoters of
active resolution of inflammation. Indeed, at the preclinical
level, therapeutic administration of SPMs has shown to
promote resolutionof inflamedadipose tissueandtoprotect
mice against obesity-associated complications such as in-
sulin resistance and NAFLD (8–12). Moreover, recent find-
ings have demonstrated that SPMs play a homeostatic role
in the human vasculature (13). However, at present, clear
proof that the production of SPMs is impaired in the sys-
temic circulation of obese subjects is still lacking.
Theaimof the current studywas toadvance the concept
of impaired resolution in human obesity as a phenome-
non dictating the inability to suppress unremitting in-
flammation in this condition. The current study explores
this possibility by comparing the production of SPMs in
peripheral leukocytes isolated from individuals with
morbid obesity with those isolated from nonobese con-
trols. The results obtained confirm that leukocytes from
obese individuals have an unbalanced formation of SPMs
with respect to proinflammatory lipid mediators such as
leukotriene (LT) B4 and prostaglandins (PGs). Moreover,
the current study provides new insights into the mecha-
nisms underlying impaired SPM formation in obese
leukocytes. Finally, the results of this study offer new
therapeutic avenues to normalize SPM production in
obese individuals through the administration of mono-
hydroxylated precursors of SPM biosynthesis.
MATERIALS AND METHODS
Study participants
Peripheral venous blood samples (10–20 ml) were collected in
EDTA tubes from 26 individuals with a body mass index (BMI)
[calculated as mass/(height)2].30 kg/m2 (obese group) and 17
individuals with a BMI ,30 kg/m2 (nonobese group). De-
mographic andclinical data anddrugusewerecollected from the
electronic medical records. All methods were carried out in ac-
cordance with the guidelines and regulations dictated by the
Ethics Committee of Clinical Investigation of the Hospital Clı́nic
and Hospital Universitari Mútua de Terrassa. Written informed
consent was obtained from all the participants.
Isolation of leukocytes, peripheral blood
mononuclear cells, and polymorphonuclear
neutrophils and cell incubations
Blood samples were centrifuged at 200 g for 10 min, and sedi-
mented cells were incubated with prewarmed ammonium-
chloride-potassium lysis buffer for 5min at room AQ:5temperature to
remove redblood cells. The sampleswere then centrifuged at 400
g for 5min at 21°C, and the supernatantswere decanted. The red
blood cell lysis procedurewas repeated twice for 5min each, and
the resulting pellet was finally washed with Dulbecco’s PBS
(DPBS) without calcium and magnesium. The isolated leuko-
cytes were enumerated and resuspended in DPBS with calcium
and magnesium (DPBS++) and incubated at a density of 33 106
cells/ml for 30 min at 37°C in a 5% CO2 atmosphere and then
challengedwith zymosanA (100 ng/ml) in the presence of either
vehicle (0.03% ethanol), eicosapentaenoic acid (EPA) (1 mM),
docosahexaenoic acid (DHA) (1 mM), 18–hydroxy-EPA (HEPE)
(1 mM), or 17S–hydroxy-DHA (HDHA) (1 mM). After 30 min
of incubation, the samples were centrifuged at 1000 g for 5 min,
and pellets and supernatants were stored at 280°C for further
analysis. Peripheral blood mononuclear cells (PBMCs) and
polymorphonuclear neutrophils (PMNs) from obese and non-
obese individualswere separated using the Ficoll-Hypaque Plus
(GE Healthcare, Waukesha, WI, USA) density gradient with
equal volumes and spunat 700g for 30minat room temperature.
After centrifugation, the Ficoll-Hypaque layers were aspirated,
and PBMCs and PMNs were collected on the corresponding
layers at densities ranging from 1.024 to 1.077 g/ml and 1.077 to
1.119 g/ml, respectively. Individual PBMC and PMN suspen-
sionswerewashed twicewithDPBS, centrifuged, resuspended in
1 ml of DPBS, and either stored at280°C for protein analysis or
fixed with 4% paraformaldehyde for immunocytochemistry.
Major facilitator superfamily domain-containing
protein 2 immunocytochemistry
IsolatedPMNsandPBMCsfromnonobeseandobese individuals
were deposited on glass slides by cytospin centrifugation
(100,000 cells/coverslip) and fixed with fresh 4% para-
formaldehyde for 20 min at room temperature followed by in-
cubation with peroxidase blocking solution (S2023; Agilent
Technologies, Santa Clara, CA, USA) for 15 min at room tem-
perature and incubated with blocking serum AQ:6[Vectastin Avidin-
BiotinComplexKit; Vector Laboratories, Burlingame, CA,USA].
The cells were then incubated overnight at 4°Cwith the primary
rabbit anti–major facilitator superfamily domain-containing
protein 2 (MFSD2A) pAb (ab105399, dilution 1/50; Abcam,
Cambridge, UnitedKingdom) followed by incubation for 30min
at room temperature with a biotinylated anti-rabbit IgG sec-
ondary antibody and incubation with avidin-biotin complex for
30 min at room temperature. Color was developed using the
diaminobenzidine substrate (Roche, Basel, Switzerland), and the
cells were counterstained with hematoxylin, mounted with
aqueous solution, and visualized in an Eclipse E600 microscope
(Nikon, Tokyo, Japan).
Targeted lipid mediator profiling
Plasma and cell incubations were placed in 2 volumes of meth-
anol containing deuterium-labeledd5-LXA4, d5-RvD2, d4-PGE2,
d4-LTB4, and d8-5S–hydroxyeicosatetraenoic acid (HETE) (500
pgeach), kept at220°C for aminimumof 45min to allowprotein
precipitation, and then centrifuged at 1500 g for 10min at 4°C.All
samples for liquid chromatography–tandemmass spectrometry
(LC-MS/MS)-based profiling were extracted using solid-phase
extraction columns as in refs. 14 and 15. Briefly, supernatants
were subjected to solid-phase extraction, and methyl formate
fractions were collected and brought to dryness. The extracts
were resuspended in methanol and water (1:1, v/v) for injection
on an LC-20ADHPLC equipped with an SIL-20AC autoinjector
(Shimadzu, Kyoto, Japan) paired with a QTrap 5500 (Sciex, Fra-
mingham,MA, USA). An Agilent Poroshell 120 EC-C18 column
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(100 mm3 4.6 mm3 2.7 mm) was kept at 50°C, and mediators
were eluted using a mobile phase consisting of methanol-
water–acetic acid of 20:80:0.01 (v/v/v) thatwas ramped to 50:50:
0.01 (v/v/v)over0.5minand then to80:20:0.01 (v/v/v) from2to
11min,maintaineduntil 14.5min,and thenrapidlyramped to98:
2:0.01 (v/v/v) for the next 0.1 min. This was subsequently
maintainedat 98:2:0.01 (v/v/v) for5.4min, and the flowratewas
maintained at 0.5ml/min. TheQTrap 5500was operated using a
multiple reaction monitoring method (14, 15). Each metabolite
was identified using established criteria, including matching re-
tention times to syntheticmaterials andauthenticmaterial and at
least 6 diagnostic ions in the tandem mass spectrum (14, 15).
Calibration curves were obtained for each lipid mediator using
synthetic and authentic standardmixtures at 0.78, 1.56, 3.12, 6.25,
12.5, 25, 50, 100, and 200 pg that gave linear calibration curves
with r2 values of 0.98–0.99.
Assessment of thromboxane B2 and 6-keto-PGF1a
Plasma levels of thromboxane (TX)-B2 and 6-keto-PGF1a were
measured via ELISA (CaymanChemicals, AnnArbor,MI,USA),
following the manufacturer’s recommendations.
Assessment of cytokines and chemokines by
Luminex xMap technology
Cytokine and chemokine levels were determined using a multi-
plexed bead-based immunoassay (Human Cytokine/
Chemokine Magnetic bead panel Premixed 38 Plex Kit; Milli-
poreSigma, Burlington,MA,USA) in a Luminex 100 Bioanalyzer
(Luminex, Austin, TX, USA). Briefly, 25 ml plasmawas added to
eachwell before the addition of 25 ml premixedmicrobeads. The
plate was incubated overnight at 4°Cwith shaking, thenwashed
and reincubated with 25 ml detection antibody for 1 h. The plate
was washed again and incubated with 25 ml streptavidin-
phycoerythrin for 30min. Finally, after 2washes, the beadswere
resuspended in 100 ml sheath fluid and analyzed in the Luminex
100 system. The readouts were analyzed with the standard ver-
sion of Milliplex Analyst software (MilliporeSigma). A 5-pa-
rameter logistic regression model was used to create standards
curves (picograms per milliliter) and to calculate the concentra-
tion of each sample. Among the 38 cytokines and chemokines,
only 15 were detected in plasma of obese and nonobese indi-
viduals: TNF-a, monocyte chemoattractant protein 1, IL-1b, -6,
-10, -17A, macrophage inflammatory protein (MIP) 1a, MIP-1b,
C-X-C motif chemokine 10, IFN-g, IL-4, granulocyteAQ:7 CSF, gran-
ulocyte M-CSF, IL-8, and IL-1RA.
Analysis of gene expression by TaqMan
low-density arrays
Isolation of total RNA from human leukocytes was performed
using Trizol reagent. RNA concentration was assessed in a
NanoDrop-1000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA, USA), and its integrity was tested with an RNA
6000 Nano Assay in a Bioanalyzer 2100 (Agilent Technologies).
cDNAsynthesis from1mg of total RNAwas performedusing the
High-Capacity cDNA Archive Kit (Thermo Fisher Scientific) and
loaded on customized TaqMan low-density array microfluidic
cards (Thermo Fisher Scientific). ProbesAQ:8 and primers for arach-
idonate 5- lipoxygenase (LOX;Hs00167536_m1), arachidonate 15-
LOX A (Hs00993765_g1), arachidonate 15-LOX B, (Hs00153988_
m1), GPR18 (Hs01921463_s1), GPR32 (Hs01102536_s1), formyl
peptide receptor 2 (Hs02759175_s1), chemerin receptor 23
(Hs010819 79_s1), housekeeping (b-actin, Hs01060665_g1), and 1
positive control for the reaction (18S, Hs99999901_s1) were
preloaded in the384wellsof eachTaqMan low-densityarraycard.
Real-timeRT-PCRamplificationswerecarriedout inanABIPrism
7900HTSequenceDetectionSystemandthe resultswereanalyzed
with the Sequence Detector Software v.2.1 (Thermo Fisher Scien-
tific). Relative quantification of gene expression was performed
using the comparative Ct method. The amount of target gene,
normalized tob-actin and relative to a calibrator,was determined
by the arithmetic equation 22DDCt described in the comparative
Ct method (https://assets.thermofisher.com/TFS-Assets/LSG/manuals/
cms_040980.pdf).
Analysis of protein expression by Western blot
Total protein from leukocytes was extracted with lysis buffer
containing 50 mM HEPE, 20 mM b-glycerophosphate, 2 mM
EDTA, 1% Igepal AQ:9, 10% (vol/vol) glycerol, 1 mM MgCl2, 1 mM
CaCl2, and 150 mM NaCl supplemented with protease (Com-
pleteMini;Roche) andphosphatase (PhosStop;Roche) inhibitors.
Homogenates were incubated on ice for 15 min and centrifuged
at 1000 g for 5minat 4°C. Total protein (50mg) fromsupernatants
wasplaced in SDS-containingLaemmli sample buffer, heated for
5min at 95°C, and separated by 10% (vol/vol) SDS-PAGE for 90
min at 120 V. Transfer onto PVDF membranes was performed
using the iBlot Dry Blotting System (Thermo Fisher Scientific) at
20V for 7min, and the efficiencyof the transferwas visualizedby
Ponceau S staining. The membranes were then soaked for 1 h at
room temperature in 0.1% T-TBS AQ:10and 5% (wt/vol) nonfat dry
milk. Blots were washed 3 times for 5 min each with 0.1% T-TBS
and subsequently incubated overnight at 4°C with primary
rabbit anti-human 5-LOX (3289, dilution 1/1000; Cell Signaling
Technology, Danvers, MA, USA), phosphorylated (phospho)–
Ser271–5-LOX (ab59395, dilution 1/500; Abcam), 5-LOX acti-
vating protein (FLAP, ab124714, dilution 1/1000; Abcam), 15-
LOX-1 (ab119774, dilution 1/500; Abcam), phospho-p44/42
MAPK (phospho-Erk1/2, 9101, dilution 1/1000; Cell Signaling
Technology), p44/42MAPK (Erk1/2, 4696, dilution 1/2000; Cell
Signaling Technology), andMFSD2A (ab105399, dilution 1/500;
Abcam) antibodies in 0.1% T-TBS containing 5% bovine serum
albumin.Thereafter, theblotswerewashed3 times for 5min each
with 0.1%T-TBS and incubated for 1 h at room temperaturewith
a horseradish peroxidase–linked donkey anti-rabbit antibody
(1:2000) in 0.1% T-TBS containing 5% nonfat dry milk, and the
bands were visualized using the EZ-ECL chemiluminescence
detection kit (Biological Industries, Cromwell, CT, USA). To as-
sess housekeeping protein expression, the membranes were
stripped at 50°C for 20 min in 100 mM b-mercaptoethanol, 2%
(vol/vol) SDS, and 62.5 mM Tris-HCl (pH 6.8) and reblotted
overnight at 4°C with primary glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (ab9485, dilution 1/2000; Abcam).
Confocal microscopy
IsolatedPMNsandPBMCsfromnonobeseandobese individuals
were plated (200,000/well) on 0.01% poly-L-lysine–precoated 8-
well chamber slides (Nunc, Lab-Tek; Thermo Fisher Scientific)
and cultured overnight with Roswell Park Memorial Institute
1640 medium containing penicillin (100 U/ml), streptomycin
(100U/ml), L-glutamine (4mM), and10% fetal bovine serum in AQ:11a
humidified 5% CO2 incubator at 37°C. The cells were fixed with
fresh 4% paraformaldehyde for 40 min at room temperature
followed by permeabilization with 0.1% Triton X-100 for 15 min
at room temperature. They were then washed, blocked with 1%
bovine serum albumin for 1 h at room temperature, and in-
cubated in a humidified chamber with anti–5-LOX antibody
(ab169755, dilution 1/100; Abcam) for 2 h at room temperature
followed by goat anti-rabbit IgG–conjugated Alexa Fluor 488
(Thermo Fisher Scientific) for 30 min at room temperature and
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counterstained with fluorescently-labeled phalloidin (P1951, di-
lution 1/1000; MilliporeSigma) andHoechst (H3570, dilution 1/
2000; Molecular Probes, Eugene, OR, USA) for 20 min at room
temperature. Coverslips were thenmounted on glass slides with
ProLongGoldantifade reagent (ThermoFisherScientific) and the
fluorescent signal was visualized with a confocal laser-scanning
microscope (ZeissLSM880;CarlZeiss,Oberkochen,Germany)at
a magnification of 3630. ImageJ software (McMaster Bio-
photonics; National Institutes of Health, Bethesda, MD, USA)
was used for image acquisition.
Intracellular calcium mobilization assay
Leukocytes from nonobese and obese individuals were seeded
(200,000/well) in a black wall and clear bottom 96-well plate
(Costar; Corning, Corning, NY, USA). The cells were incu-
bated with 100 ml fura-2 for 1 h at 37°C according to the Fura-2
No Wash Calcium Assay Kit (Abcam) instructions, and N-
formylmethionyl-leucyl-phenylalanine (100 nM) or zymosan A
(100 ng/ml) were added to induce GPCR agonist–mediated in-
tracellular calcium release. Fluorescence intensities were moni-
tored at excitations of 340 and 380 nm and at an emission of 510
nm.
Statistical analysis
Statistical analysis of the results was performed by ANOVA (1-
way or 2-way ANOVA) or the unpaired Student’s t test. Results
are expressed as mean 6 SEM and differences considered signif-
icant at P, 0.05.
RESULTS
The demographic and clinical characteristics of the pa-
tients included in the study are shown in Supplemental
Table S1.As comparedwithnonobese individuals (n=17),
the obese group (n = 26) had an increased BMI and fasting
serum glucose and triglycerides levels and a higher white
blood cell count at the expense of a higher neutrophil
count, with no changes in serum cholesterol, g-glutamyl
transpeptidase, and alanine and aspartate aminotransfer-
ase concentrations.Therewerenosignificantdifferences in
age between the study groups (Supplemental Table S1).
Multianalyte profiling of circulating cytokines and che-
mokines revealed that obese individuals had increased
plasma levels ofmonocyte chemoattractant protein 1, IL-6,
IL-17A,MIP-1b,C-X-Cmotif chemokine10, IFN-g, and IL-
1RA as compared with nonobese subjects, indicating a
higher systemic inflammatory tone in obesity (Supple-
mentalTable S2). TheLC-MS/MSprofiling of the essential
polyunsaturated fatty acids and the bioactive lipid medi-
ators derived from these fatty acids (see a schematic dia-
gram in Fig. 1A) revealed similar plasma levels of
arachidonic acid (AA), EPA, and DHA (Fig. 1B) and a
similar AA:EPA+DHA abundance ratio (Fig. 1C) in obese
and nonobese individuals. The most abundant lipid me-
diators in the circulation, which in addition were signifi-
cantly decreased in plasma of obese individuals, were
TXB2 (the inactive stablemetabolite of TXA2) (Fig. 1D) and
12-HETE (Fig. 1E) derived from AA via cyclooxygenase
(COX) and 12-LOXpathways, respectively. Of interest, no
changes in the ratio between the stable PGI2 metabolite 6-
keto-PGF1a and TXB2 were observed when both eicosa-
noids were measured by ELISA, despite the fact that both
lipid mediators were significantly decreased in the obese
group (Supplemental Fig. S1). Other lipid mediators that
were significantly reduced in obese individuals were the
monohydroxylated fatty acids 14-HDHA and 17-HDHA
derived from DHA and 15-HETE derived from AA (Fig.
1E). In addition, the cytochrome P450 (CYP) products
20-HETE and 18-HEPE, derived from AA and EPA, re-
spectively, were also significantly reduced (Fig. 1F). Fi-
nally, we assessed the plasma levels of SPM in obese
individuals and compared them with those in nonobese
controls. LC-MS/MS analysis for these lipid mediators
was performed according to published criteria AQ:12that in-
cludematching retention times and at least 6 characteristic
and diagnostic ions for each, as illustrated with the chro-
matographic peak and the spectrum obtained for RvD5
(Fig. 1G). As shown in Fig. 1H, the formation of 15-LXA4,
an AA-derived SPM generated through the interaction of
15-LOX with 5-LOX, was significantly reduced in plasma
of obese individuals. The plasma levels of RvD2andRvD4
were also lower in obese individuals, although changes
did not reach statistical significance (Fig. 1H). Taken to-
gether, these results indicate that in the context of low-
grade systemic inflammation, obese individuals exhibit an
impaired conversion of polyunsaturated fatty acids to
downstream products.
Because bioactive lipid mediators in the circulation are
mostly produced by cells of the immune system, we next
characterized the LC-MS/MS profile of lipid mediators
endogenouslyproducedbycirculating leukocytes isolated
from obese and nonobese individuals. Leukocytes from
obese individuals presented a significantly lower content
of the polyunsaturated fatty acidDHA (Fig. 2A), although
the AA:EPA+DHA ratio was similar in both groups (Fig.
2B). Moreover, the profile of lipid mediators in leukocytes
resembled that seen in plasma, with TXB2 and 12-HETE
followed by 15-HETE, 17-HDHA, 18-HEPE, LTB4, and 20-
HETE being the most abundant (Fig. 2C–E). However,
levels of lipid mediators were different depending on
whether the leukocytes were isolated from obese or non-
obese individuals. In particular, leukocytes from obese
subjects showed a 4-fold increase in LTB4 and 20-HETE
(Fig. 2D, E) in parallel with impaired capacity to generate
monohydroxylatedDHA- andEPA-derivedproducts (i.e.,
17-HDHA and 18-HEPE) (Fig. 2D, E). Furthermore, a full
array of DHA-derived SPM produced via 12-LOX (i.e.,
MaR1 and MaR2) and 15-LOX (i.e., protectin D1) path-
ways (Fig. 2D) and via 15-LOX and 5-LOX interaction (i.e.,
RvD4, -5, -2, -1, -6, and -3; in order of abundance) (Fig. 2F)
were detected in leukocytes from obese and nonobese
subjects.Other SPMs, such asRvs of the E series (i.e., RvE1,
-2, and -3) (Fig. 2E), andLXA4andLXB4 (Fig. 2F) generated
from EPA and AA, respectively, were also identified. Pie
charts depicting the distribution of lipids identified in
leukocytes from obese and nonobese individuals are
shown in Fig. 2G. Importantly, leukocytes from obese in-
dividuals showed a significantly reduced ratio of DHA-
derived SPM production with respect to the levels of
classic inflammatory lipid mediators such as LTB4 and
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PGs (Fig. 3A), a finding that was not as evident in the
production of EPA-derived SPMs. Figure 3B provides a
detailed distribution of the SPM fractions in these cells
from both groups of study.
To investigate the mechanisms responsible for the un-
balanced formation of DHA-derived SPMs in leukocytes
from obese individuals, we next explored the critical steps
involved in the biosynthesis of these proresolving media-
tors in circulating leukocytes. First, we addressed the cel-
lular DHA uptake through the membrane transporter
MFSD2A (16). As shown in Fig. 4A, immunocytochemis-
try analysis showed that the MFSD2A protein is consti-
tutively expressed in both human PMNs and PBMCs. Of
note, the levels of MFSD2A protein expression were sig-
nificantly reduced in PMNs and PBMCs from obese indi-
viduals as compared with those from nonobese controls
(Fig. 4B). Because after being taken up by activated
leukocytes, DHA is converted into 17-HDHA by 15-LOX,
we next assessed the expression of this enzyme in leuko-
cytes from obese individuals. As shown in Fig. 4C, mRNA
expression for 15-LOX-1 and 15-LOX-2 (the 2 15-LOX
isoenzymes) were not suppressed but rather increased in
leukocytes from obese individuals. Moreover, similar
protein levels of 15-LOX-1 were observed in PMNs and
PBMCs (Fig. 4D). To determine the relative contribution of
each of these 2 mechanisms to the impaired formation of
DHA-derived SPMs in obesity, we incubated leukocytes
from obese and nonobese individuals with DHA and
measured the levels of 17-HDHAproduced by these cells.
As compared AQ:13with nonobese leukocytes, obese leukocytes
released lower quantities of 17-HDHA from exogenous
DHA, indicating either reduced uptake of the fatty acid or
reduced 15-LOX activity in these cells (Fig. 4E). However,
the levels of other monohydroxy fatty acids derived en-
zymatically (14-HDHA by 12-LOX) and nonenzymati-
cally (13-HDHA, 7-HDHA, and 4-HDHA) from DHA
were not significantly decreased (Fig. 4E). The finding AQ:14that
only 17-HDHA biosynthesis is dependent on 15-LOX to-
gether with the observation that endogenous production
of other monohydroxy fatty acids was either not differ-
ent or even increased in obese leukocytes (Fig. 4F) sup-
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Figure 1. A) SchematicAQ:21 diagram of the biosynthesis of lipid mediators derived from AA, EPA, and DHA. B) Plasma levels of AA,
EPA, and DHA in nonobese (n = 10) and obese (n = 20) subjects as analyzed by LC-MS/MS. C) Plasma AA:(EPA+DHA) ratio in
obese and nonobese subjects. D) Plasma levels of COX products derived from AA. E) Plasma levels of 5-, 12-, and 15-LOX
products derived from AA and DHA. PD1, protectin D1. F) Plasma levels of CYP and CYP and LOX products from AA anAQ:22 d EPA.
G) Representative chromatogram and mass spectrum used in the identification of RvD5 by LC-MS/MS–based metabololipi-
domics. H) Plasma levels of 15-LOX and 5-LOX products from AA and DHA. Non-Ob, nonobese; Ob, obese. Results are
expressed as means 6 SEM. *P , 0.05, **P , 0.01 vs. Non-Ob group.






















































































































































Figure 2. A) Levels of polyunsaturated fatty acids (AA, EPA, and DHA) in isolated leukocytes from nonobese (n = 5) and obese
(n = 6) subjects as analyzed by LC-MS/MS. B) AA:(EPA+DHA) ratio in obese and nonobese individuals. C) Levels of COX products
derived from AA. D) Levels of 5-, 12-, and 15-LOX products derived from AA and DHA. E) Levels of CYP and CYP and LOX
products from AA and EPA. F) Levels of 15-LOX and 5-LOX products from AA and DHA. G) Pie charts of lipid distribution in
leukocytes from obese and nonobese individuals. Non-Ob, nonobese; Ob, obese. Results are expressed as means 6 SEM. *P , 0.05
vs. nonobese group.
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outweighing the importance of themembrane transporter
MFSD2A.
Because 17-HDHA is subsequently converted into Rvs
of theD series by5-LOX,wenext assessed the expressionof
this enzyme in leukocytes from obese individuals. As
compared with nonobese controls, obese leukocytes
showed not only reduced 5-LOX and FLAP protein ex-
pression but also decreased phosphorylation of the Ser271
of the 5-LOX enzyme (Fig. 5A). These findings not only
indicate a lower amount of 5-LOX enzyme in obese cells
but also suggest a distinct localization and redistribution
of this enzyme in leukocytes from obese individuals
(17–19). Indeed, confocal microscopy imaging revealed
that in contrast to nonobese individuals, in whom the 5-
LOX signal is abundant and preferentially cytoplasmic,
the 5-LOX signal in obese subjects is less intense andmore
diffusively distributed (Fig. 5B). Figure 5B shows results in
PMNs, but similar findingswere observed inPBMCs from
obese individuals (Supplemental Fig. S2). No changes
were seen in Erk1/2 phosphorylation, the upstream ki-
nases that phosphorylate the Ser663 residue in the 5-LOX
enzyme (20) (Fig. 5C), and in intracellular calcium mobi-
lization (Fig. 5D),which is a critical factor for the activation
of the enzymaticmachinery necessary for the biosynthesis
of bioactive lipidmediators. Taken together, these findings
point to the fact that SPM biosynthesis in leukocytes from
obese individuals could also be compromised bypoor and
unusual intracellular 5-LOX distribution.
We finally monitored the levels of Rvs of the D series in
leukocytes incubated with either the parent fatty acid (i.e.,
DHA)or the intermediatemonohydroxy fatty acid (i.e., 17-
HDHA). To assist in understanding these experiments, a
simplified scheme of the biosynthesis of D-series Rvs is
provided in Fig. 6A. As expected, both DHA and 17-
HDHAinduced the formationofRvsof theD series (RvD1,
-2, -3, -4, -5, and -6) by leukocytes from healthy donors,
with the conversion being more efficient for 17-HDHA
than for its parent compoundDHA (Fig. 6B). Similarly, the
conversion to D-series Rvs was also more efficient for 17-
HDHA than for DHA in leukocytes from obese individ-
uals (Fig. 6C). Importantly, when leukocytes from obese
individuals were incubated with equimolar concentra-
tionsof 17-HDHA, a similar, if not higher, productionof D-
series Rvs (especially of RvD5) compared with leukocytes
from nonobese controls was observed (Fig. 6C). In-
terestingly, 17-HDHA, but not DHA, significantly re-
duced LTB4 release and leukocyte 5-LOX expression
(Supplemental Fig. S3A, B). No changes in PG production
were seen in these incubations (Supplemental Fig. S3C). It
is of major interest that the ratios between D-series Rvs
with respect to PGs and LTB4 were normalized in leuko-
cytes from obese subjects when these cells were incubated
with 17-HDHA (Fig. 6D). Similar findings were observed
with respect to the formation of Rvs of the E series, when
leukocyteswere incubatedwith the18-HEPE intermediate
or its parent compound EPA, in which 18-HEPE was a
moreefficient substrate for conversion intoRvE1, -2, and-3
and normalized the conversion ratio into Rvs of the E se-
ries (Supplemental Fig. S4). Notably, 18-HEPE showed a

























































Figure 3. A) DHA- and EPA-derived SPM:LTB4
(including all LTB4 metabolome) and DHA- and
EPA-derived SPM:PG ratios in leukocytes isolated
from nonobese (n = 5) and obese (n = 6)
individuals. B) Pie charts of detailed SPM
distribution in leukocytes from obese and non-
obese individuals. Non-Ob, nonobese; Ob, obese.
Results are expressed as means 6 SEM. *P , 0.05,
**P , 0.01 vs. nonobese group.
PRORESOLVING LIPID MEDIATOR BIOSYNTHESIS IN OBESITY 7
chemerin receptor 23, GPR18, GPR32, and formyl peptide
receptor 2 in leukocytes from obese individuals (Supple-
mentalFig. S5), a finding that canbe interpretedasa return
to homeostasis of the expression of most of the SPM
receptors.
DISCUSSION
Obesity is associatedwith a generalized state of low-grade
inflammation, which is a major risk factor for developing
comorbidities within the context of the metabolic syn-
drome (21). Indeed, obese individuals have an enhanced






















































































































































Figure 4. A) Representative immunocytochemistry images of MFSD2A transporter protein staining in PMNs and PBMCs from
nonobese (n = 16) and obese (n = 16) individuals. Original magnification, 3100 (upper panel); original magnification, 3200
(bottom panel). Zoomed images are included in insets. B) Representative immunoblots of MFSD2A and GAPDH assessed by
Western blot in PMNs and PBMCs isolated from nonobese (n = 16) and obese subjects (n = 16). The densitometric analyses of
MFSD2A signal normalized to GAPDH are shown at the bottom. C) Gene expression of 15-LOX-1 and 15-LOX-2 enzymes in
leukocytes from nonobese and obese individuals. D) Representative immunoblots of 15-LOX-1 and GAPDH assessed by Western
blot in PMNs and PBMCs isolated from nonobese (n = 16) and obese subjects (n = 16). The densitometric analyses of 15-LOX-1
signal normalized to GAPDH are shown at the right. E, F) Production of DHA-derived monohydroxy fatty acids from exogenous
(E) and endogenous (F) sources in leukocytes from nonobese (n = 5) and obese (n = 6) subjects. Non-Ob, nonobese; Ob, obese.
Results are means 6 SEM from 3 independent experiments assayed in quadruplicate.
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cardiovascular disease as well as NAFLD, a condition
that represents the hepatic manifestation of the meta-
bolic syndrome (21). ConsideringAQ:15 the growing number of
individuals affected by the current epidemic of obesity,
especially the number of overweight children, the imple-
mentationofnovel targeted strategies for thepreventionof
obesity-associated comorbidities is a matter of major in-
terest. In this context, and considering that current anti-
inflammatory therapies (i.e., nonsteroidal anti-
inflammatory and biologic drugs) are not an option for
these patients because of their potential side effects,
boosting the resolution of inflammation through in-
creasing the formation of endogenous proresolving me-
diators is a well-positioned strategy to curve the risks
associated with obesity-induced inflammation. The cur-
rent study provides relevant data in relation with this
potential therapy. First, our findings confirm the inability
of the immune systems of obese individuals to efficiently
resolve the unremitting systemic inflammation that
persists in this condition. Second, our results provide evi-
dence of an unbalanced situation in leukocytes fromobese
individuals between the enhanced formation of lipid me-
diators with proinflammatory properties and the forma-
tion of lipid mediators with proresolving activity (e.g.,
SPMs). Third, our study provides novel mechanistic in-
sights on the impaired formation of SPMs in leukocytes
from obese individuals. Finally, our data provide proof of
concept that intermediate precursors of SPM biosynthesis
(i.e., 17-HDHA and 18-HEPE) have the ability to override
the impaired formation of these proresolving lipid medi-
ators by obese leukocytes.
Previous studies from our laboratory and others have
provided evidence of a heightened proinflammatory
phenotype alongwith a compromised capacity toproduce
SPMs in white adipose tissue from obese individuals and
from experimental models of obesity, including high-fat
diet–induced obese, ob/ob obese, and db/db obese and di-







































































































































































Figure 5. A) Protein expression of phospho–5-LOX (Ser271), total 5-LOX, FLAP, and GAPDH in PMNs from nonobese (n = 16)
and obese (n = 16) subjects assessed by Western blot analysis. The densitometric analyses of phospho–5-LOX, total 5-LOX, and
FLAP signals normalized to GAPDH are shown at the bottom. B) Representative confocal laser scanning microscopy images of
labeled 5-LOX (green), F-actin (phalloidin, red), and nuclei (DAPI, blue) in PMNs of nonobese (n = 4) and obese (n = 4)
individuals at original magnification, 3630. Merged images are shown in the bottom panel. Representative zoomed images at 3.0
times are also given (middle). C) Representative immunoblots of phosphoAQ:23 -Erk1/2 and total Erk1/2 protein expression from
nonobese (n = 16) and obese subjects (n = 16). The densitometric analyses of phospho-Erk1/2 and total Erk1/2 signals
normalized to GAPDH are shown at the bottom. D) Intracellular calcium mobilization in leukocytes isolated from nonobese (n =
3) and obese (n = 3) individuals incubated with either vehicle, N-formylmethionyl-leucyl-phenylalanine (100 nM), or zymosan A
(100 ng/ml) for 1 h at 37°C/5% CO2. fMLP, N-formylmethionyl-leucyl-phenylalanine; Non-Ob, nonobese; Ob, obese; Zym A,
zymosan A. Results are means 6 SEM from 3 independent experiments assayed in quadruplicate.
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D-series Resolvins/PGs D-series Resolvins/LTB4
Figure 6. A) SchematicAQ:24 diagram of the biosynthesis of D-series Rvs through the actions of 15- and 5-LOX. B) Levels of D-series Rvs
(RvD1, -2, -3, -4, -5, and -6) in leukocytes isolated (3 3 106 cells/condition) from healthy donors incubated with either vehicle
(0.3% ethanol), 17-HDHA (1 mM), or DHA (1 mM) in the presence of zymosan A (100 ng/ml) for 30 min at 37°C/5% CO2. C)
Levels of D-series Rvs in leukocytes isolated from nonobese (n = 5) and obese (n = 6) individuals incubated with vehicle, 17-
HDHA, or DHA in the presence of zymosan A for 30 min at 37°C/5% CO2. Calculation of DHA-derived SPM:DHA and DHA-
derived SPM:17-HDHA ratios in leukocytes from nonobese and obese subjects is shown as an inset. D) Ratios of D-series Rv:PG
and D-series Rv:LTB4 in leukocytes from nonobese and obese individuals. Non-Ob, nonobese; Ob, obese; Veh, vehicle. Results are
means 6 SEM from 6 independent experiments assayed in duplicate. *P , 0.05, **P , 0.01, ***P , 0.001 vs. vehicle or nonobese
group.
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expanded this concept of unbalanced SPM formation in
obese white adipose tissue to the systemic circulation. In-
deed, amajor novelty of our studywas the demonstration
that the existing imbalance between enhanced formation
ofproinflammatory lipidmediators comparedwith that of
SPMs also takes place in peripheral blood leukocytes iso-
lated from individuals with morbid obesity. This obser-
vation has a major implication because it suggests that
unresolvedandunremitting inflammation is ageneralized
and common event in obesity. Moreover, our in vitro
findings in leukocyte incubations suggest that unresolved
inflammation in obesity is the result of impaired leukocyte
SPM biosynthesis rather than increased loss of SPMs sec-
ondary to accelerated SPM inactivation (23).
Biosynthesis of the SPMs of the Rv D family is a com-
plex process that involves the engagement of 15- and 5-
LOX enzymes (6). In particular, the formation of D-series
Rvs requires the initial conversion by 15-LOX of the
omegaAQ:16 -3 parent precursor DHA into 17-HDHA and the
subsequent transformation by 5-LOX of this intermediate
into 6 different molecular entities, namely RvD1, -2, -3, -4,
-5, and -6 (26, 27). Indeed, the endogenous production of
17-HDHA was significantly reduced in leukocytes from
obese individuals, an impairment that was also observed
when these leukocytes were incubated with exogenous
concentrations of DHA. This finding could be caused by a
reduced uptake of DHA because in obese leukocytes, we
found a remarkable decrease in the protein levels of the
membrane transporter MFSD2A required for the cellular
incorporation of DHA (16, 28). However, the observation
that only 17-HDHA (derived from DHA through the ac-
tivity of 15-LOX) was significantly reduced in obese
leukocytes in the absence of changes in other mono-
hydroxy fatty acids enzymatically (14-HDHAby 12-LOX)
ornonenzymatically (13-HDHA,7-HDHA,and4-HDHA)
derived from DHA suggests compromised 15-LOX activ-
ity in this condition. This is a potential mechanism that
needs to be further explored, despite the fact that the ex-
pression of the 15-LOX isoenzymes was not reduced in
obese leukocytes. In addition to this, our data demon-
strated that 5-LOX protein levels and phosphorylation of
Ser271 of 5-LOX were significantly reduced in leukocytes
from obese individuals. Because Ser271 phosphorylation
has been shown to inhibit thenuclear export of 5-LOX (29),
these findings suggest that in obese leukocytes, 5-LOX
would be mostly localized in the cytoplasm instead of the
nucleus, which is a trait that would favor and not hamper
the biosynthesis of SPMs by these cells (30–33). However,
confocal microscopy analyses could not confirm this
counterintuitive finding and only proved a less intense 5-
LOXsignal andadistinct intracellular redistributionof this
enzyme in leukocytes from obese individuals. This find-
ing, together with the absence of changes in the in-
tracellular calcium mobilization and phosphorylation of
upstream kinases implicated in the regulation of 5-LOX
activity, supports the concept that impaired SPM pro-
ductionbyobese leukocytes cannot simplybeattributed to
a dysfunctional 5-LOX pathway. This view is supported
by the finding that the amount of D-seriesRvsproducedby
obese leukocytes was similar to that of healthy leukocytes
when they were incubated with exogenous 17-HDHA,
which is dependent on 5-LOX to convert into D-series Rvs.
Collectively, thesedatasuggest thatunbalanced formation
ofRvsof the D serieswith respect to proinflammatory lipid
mediators such as LTB4 in obese leukocytes could be the
consequence of reduced 15-LOX activity together with a
defective 5-LOX distribution.
In summary, our study provides data indicating that
obese individuals produce an unbalanced amount of the
proresolving lipid mediators derived from DHA (i.e., Rvs
of the D series) in peripheral leukocytes, and this is ac-
companied by an enhanced formation of lipid mediators
withproinflammatoryproperties.The impaired formation
of theseDHA-derivedSPMs is likely theconsequenceofan
alteration in LOX activity, expression, or subcellular lo-
calization, leading to analtered15-LOX/5-LOXsequential
biosynthesis of SPMs. Notably, impaired formation of
DHA-derived SPMs can be rescued by supplementation
with the intermediateprecursor 17-HDHA.These findings
open new avenues for alternative approaches to the use of
omega-3 fatty acids AQ:17as a nutrition therapy to boost SPM
formation to promote the resolution of inflammation. For
instance, supplementation with the intermediate (i.e., 17-
HDHA) instead of the parent precursor (i.e., DHA) could
be of major significance in overcoming impaired SPM
formation in conditions in which DHA metabolism is
compromised, such as in the case of obesity.
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C AQ:20. López-Vicario and J. Clària conceived and designed the
experiments; C. López-Vicario performed the experi-
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4. Unamuno, X., Gómez-Ambrosi, J., Rodrı́guez, A., Becerril, S.,
Frühbeck, G., and Catalán, V. (2018) Adipokine dysregulation and
adipose tissue inflammation in human obesity. Eur. J. Clin. Invest. 48,
e12997
5. Lumeng, C. N., and Saltiel, A. R. (2011) Inflammatory links between
obesity and metabolic disease. J. Clin. Invest. 121, 2111–2117
6. Serhan, C. N. (2014) Pro-resolving lipid mediators are leads for res-
olution physiology. Nature 510, 92–101
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J. (2011) Resolvin D1 and its precursor docosahexaenoic acid
promote resolution of adipose tissue inflammation by eliciting
macrophage polarization toward an M2-like phenotype. J. Immunol.
187, 5408–5418
11. Rius, B., Titos, E., Morán-Salvador, E., López-Vicario, C.,
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